Computer-Aided Drug Design of Falcipain Inhibitors: Virtual Screening, Structure-Activity Relationships, Hydration Site Thermodynamics, and Reactivity Analysis
暂无分享,去创建一个
Woody Sherman | Mitchell A. Avery | Falgun Shah | Philip J. Rosenthal | Jiri Gut | Jennifer Legac | Devleena Shivakumar | J. Gut | P. Rosenthal | W. Sherman | Devleena Shivakumar | J. Legac | M. Avery | F. Shah
[1] J T Palmer,et al. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors , 1996, Antimicrobial agents and chemotherapy.
[2] P. Rosenthal,et al. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[3] R. Wilson,et al. Plasmodium falciparum: protease inhibitors and inhibition of erythrocyte invasion. , 1986, Experimental parasitology.
[4] Ashutosh Kumar Singh,et al. Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. , 2001, The Biochemical journal.
[5] Bruce Russell,et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription , 2011, BMC Genomics.
[6] Jean-François Truchon,et al. A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. , 2007, Bioorganic & medicinal chemistry letters.
[7] Marcin Wiśniewski,et al. [Achievements and perspectives of research into development of a vaccine against malaria]. , 2010, Wiadomosci parazytologiczne.
[8] Juan Miguel,et al. Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. , 2010, Journal of medicinal chemistry.
[9] William R. Roush,et al. Structure-Activity Relationships for Inhibition of Cysteine Protease Activity and Development of Plasmodium falciparum by Peptidyl Vinyl Sulfones , 2003, Antimicrobial Agents and Chemotherapy.
[10] D. Davis,et al. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity. , 2003, Bioorganic & medicinal chemistry letters.
[11] James R Kiefer,et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. , 2010, Journal of molecular biology.
[12] B. Berne,et al. Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. , 2008, Journal of the American Chemical Society.
[13] Mitchell A. Avery,et al. Design, Synthesis and Evaluation of Trisubstituted Thiazoles Targeting Plasmodium Falciparum Cysteine Proteases , 2005, Medicinal Chemistry Research.
[14] Markus Hardt,et al. Hemoglobin Cleavage Site-Specificity of the Plasmodium falciparum Cysteine Proteases Falcipain-2 and Falcipain-3 , 2009, PloS one.
[15] Prasenjit Mukherjee,et al. Computational approaches for the discovery of cysteine protease inhibitors against malaria and SARS. , 2010, Current computer-aided drug design.
[16] F E Cohen,et al. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[17] K. Silamut,et al. Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.
[18] David A. Fidock,et al. Drug discovery: Priming the antimalarial pipeline , 2010, Nature.
[19] Jiri Gut,et al. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. , 2004, Journal of medicinal chemistry.
[20] Carlos R Rodrigues,et al. Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies. , 2002, Journal of medicinal chemistry.
[21] E. Shaw,et al. Inhibition of intraerythrocytic development of Plasmodium falciparum by proteinase inhibitors , 1990, FEBS letters.
[22] P. Rosenthal,et al. Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease. , 1997, Journal of medicinal chemistry.
[23] W. C. Still,et al. Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .
[24] George M. Whitesides,et al. Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase , 2011, Proceedings of the National Academy of Sciences.
[25] Sanjay Batra,et al. Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-trisubstituted dihydroisoquinolines and isoquinolines. , 2003, Bioorganic & medicinal chemistry.
[26] Maria Zappalà,et al. Falcipain‐2 Inhibitors , 2010 .
[27] P. Rosenthal,et al. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. , 1993, The Journal of clinical investigation.
[28] W. Milhous,et al. Structure-activity relationships of the antimalarial agent artemisinin. 2. Effect of heteroatom substitution at O-11: synthesis and bioassay of N-alkyl-11-aza-9-desmethylartemisinins. , 1995, Journal of medicinal chemistry.
[29] Honglin Li,et al. Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. , 2009, Journal of medicinal chemistry.
[30] Themis Lazaridis,et al. Inhomogeneous Fluid Approach to Solvation Thermodynamics. 2. Applications to Simple Fluids , 1998 .
[31] Tobee Chung,et al. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity. , 2003, Bioorganic & medicinal chemistry letters.
[32] W. Sherman,et al. Understanding Kinase Selectivity Through Energetic Analysis of Binding Site Waters , 2010, ChemMedChem.
[33] Jiri Gut,et al. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. , 2006, Journal of medicinal chemistry.
[34] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[35] Jennifer Legac,et al. Vinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug Design* , 2009, The Journal of Biological Chemistry.
[36] P. Rosenthal,et al. Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. , 1995, Experimental parasitology.
[37] Rolf Hilgenfeld,et al. Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.
[38] C. Dolea,et al. World Health Organization , 1949, International Organization.
[39] Mitchell A. Avery,et al. Identification of Novel Malarial Cysteine Protease Inhibitors Using Structure-Based Virtual Screening of a Focused Cysteine Protease Inhibitor Library , 2011, J. Chem. Inf. Model..
[40] Woody Sherman,et al. High‐energy water sites determine peptide binding affinity and specificity of PDZ domains , 2009, Protein science : a publication of the Protein Society.
[41] Prashant Desai,et al. Homology Modeling of Falcipain-2: Validation, De Novo Ligand Design and Synthesis of Novel Inhibitors , 2002, Journal of biomolecular structure & dynamics.
[42] P. Rosenthal,et al. Cysteine proteases of malaria parasites. , 2004, International journal for parasitology.
[43] Falgun Shah,et al. Design, synthesis, and development of novel guaianolide-endoperoxides as potential antimalarial agents. , 2010, Journal of medicinal chemistry.
[44] Woody Sherman,et al. Contribution of Explicit Solvent Effects to the Binding Affinity of Small‐Molecule Inhibitors in Blood Coagulation Factor Serine Proteases , 2011, ChemMedChem.
[45] Mitchell A. Avery,et al. Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors , 2011 .
[46] P. Rosenthal,et al. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. , 1999, Bioorganic & medicinal chemistry.
[47] Themis Lazaridis,et al. Thermodynamic contributions of the ordered water molecule in HIV-1 protease. , 2003, Journal of the American Chemical Society.
[48] W. Milhous,et al. Structure-activity relationships of the antimalarial agent artemisinin. 1. Synthesis and comparative molecular field analysis of C-9 analogs of artemisinin and 10-deoxoartemisinin. , 1993, Journal of medicinal chemistry.
[49] Robert Abel,et al. Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.
[50] C. Higgs,et al. Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. , 2010, ACS medicinal chemistry letters.
[51] J T Palmer,et al. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. , 1991, The Journal of clinical investigation.
[52] D. Fidock,et al. In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. , 2008, International journal for parasitology.
[53] Fred E. Cohen,et al. In vitro antimalarial activity of chalcones and their derivatives. , 1995, Journal of medicinal chemistry.
[54] J. Karle,et al. Structure-activity relationships of the antimalarial agent artemisinin. 3. Total synthesis of (+)-13-carbaartemisinin and related tetra- and tricyclic structures. , 1996, Journal of medicinal chemistry.
[55] M. Avery,et al. Structure-activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10-deoxoartemisinin substituted at C-3 and C-9. , 1996, Journal of medicinal chemistry.
[56] P. Kollman,et al. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .
[57] M. Ramjee,et al. Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery. , 2006, The Biochemical journal.
[58] Linda S. Brinen,et al. Structures of Falcipain-2 and Falcipain-3 Bound to Small Molecule Inhibitors: Implications for Substrate Specificity‡ , 2009, Journal of medicinal chemistry.
[59] Gabriele Costantino,et al. Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: From TIQ-A to HYDAMTIQ , 2011 .
[60] Y. Ru,et al. Cyclic ketone inhibitors of the cysteine protease cathepsin K. , 2001, Journal of medicinal chemistry.
[61] T. Lazaridis. Inhomogeneous Fluid Approach to Solvation Thermodynamics. 1. Theory , 1998 .
[62] Mitchell A. Avery,et al. Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits , 2008, Bioorganic & Medicinal Chemistry.
[63] F E Cohen,et al. In vitro antimalarial activity of chalcones and their derivatives. , 1995, Journal of medicinal chemistry.
[64] W. Charman,et al. Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates. , 2002, Journal of medicinal chemistry.